SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cash Cat

Cash Cat is generating intense debate as community members push it as a primary memecoin within the Robinhood ecosystem, with many bulls accumulating into weakness based on its perceived utility and potential for broader market adoption. Meanwhile, critics remain skeptical of its long-term viability, viewing it as another speculative asset amidst a crowded and volatile memecoin landscape.

Flowers Foods, Inc. engages in the production and marketing of packaged bakery foods. It offers breads, buns, rolls, snack items, bagels, English muffins, and tortillas and are sold under a variety of brand names, including Nature’s Own, Dave’s Killer Bread, Wonder, Canyon Bakehouse, Tastykake, and Mrs. Freshley’s. The company was founded by William Howard Flowers, Sr. and Joseph Hampton Flowers, Jr. in 1919 and is headquartered in Thomasville, GA.

Flowers Foods, Inc.

Flowers Foods is trending due to intense community discussion regarding a potential short squeeze, with investors pointing to a high short interest, low float, and speculative buyout rumors. The community is actively debating the stock's undervaluation ahead of upcoming earnings, citing the resilience of consumer staple demand and the potential for short covering to drive price momentum.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is seeing heightened market attention as investors weigh its critical role in RWA tokenization against persistent price stagnation, with ongoing discussions centered on institutional partnerships and the potential for a long-term supply/demand pivot. While some community members remain frustrated by the asset's recent performance compared to other altcoins, others are doubling down on its utility as the foundational bridge for decentralized finance and AI infrastructure.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is seeing significant investor attention ahead of its third-quarter maintenance study data, which the community views as a critical catalyst for validating VK2735's long-term efficacy. While the stock has experienced recent volatility and discussions regarding a new shelf registration, sentiment remains heavily focused on the potential for the drug to compete as a best-in-class GLP-1 agonist, with many investors anticipating an eventual partnership or buyout by major pharmaceutical players.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is seeing increased volatility and heavy investor scrutiny following the recent earnings report, with the community actively debating the company's aggressive M&A strategy and AI-driven growth potential versus current valuation concerns. Analysts are divided, balancing long-term optimism regarding AI-security demand against near-term caution regarding how effectively these acquisitions will convert into revenue in the current enterprise spending environment.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending as investors react to the company's integration of its Qwen AI model with Apple Intelligence in China, a move the community views as a significant expansion of its AI footprint. Market participants are debating whether this technology catalyst, combined with ongoing share buybacks, provides enough value to re-rate the stock despite broader concerns regarding Chinese regulatory risks and consumer spending.

Workday, Inc. engages in the development of enterprise cloud applications for finance and human resources. The firm delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. It operates through the Cloud Applications segment. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is trending as investors react to widespread buyout rumors involving private equity firm Silver Lake, which triggered multiple volatility halts and fueled significant speculation across the software sector. Community discussion is heavily divided between traders betting on a high-premium acquisition and skeptics who view the price action as a speculative pump trap disconnected from fundamentals.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visa is currently trending due to intense market anticipation surrounding its upcoming earnings report, with sentiment divided between concerns over geopolitical headwinds and optimism for resilient payment volumes. Investors are closely scrutinizing whether the company's aggressive share repurchase programs and new AI-driven commerce initiatives will be enough to fuel a breakout above recent consolidation levels.

SiTime Corp.is a micro-electromechanical system-based silicon timing solution. The company is transforming the timing industry with configurable solutions that replace legacy quartz devices and enable customers to differentiate their products with performance, smaller size, lower power, and reliability. The company was founded by Markus Lutz and Aaron Partridge on December 3, 2003 and is headquartered in Santa Clara, CA.

SiTime Corp

SiTime is trending as investors digest a strong earnings report and the strategic acquisition of Renesas' timing business, signaling significant growth potential in AI infrastructure and high-performance timing solutions. The community is actively discussing the stock's impressive technical recovery, the long-term outlook for its precision technology in AI data centers, and the debut of leveraged ETFs providing new ways to trade the semiconductor name.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing significant volatility and price appreciation driven by investor optimism surrounding its expanding pipeline, specifically the upcoming FDA decision on its mRNA-based seasonal flu vaccine and ongoing clinical progress with its personalized cancer therapy, V940. The community is actively debating the stock's long-term commercial potential and oncology market strategy while heavily monitoring high short interest, which has fueled discussions regarding a potential short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of +18.18% and -80.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why

CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire SAN FRANCISCO, July 6, 2026 Issued on...

REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics 

Regeneron expands its CytomX partnership to develop conditionally activated bispecific cancer therapies, with potential milestones nearing $4 billion.

CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of +29.58% and +193.76%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Beats Revenue Estimates

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of +3.47% and +8.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

CytomX Therapeutics (CTMX) Expected to Announce Quarterly Earnings on Thursday

CytomX Therapeutics (NASDAQ:CTMX) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-cytomx-therapeutics-inc-stock...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of "Moderate Buy" from Analysts

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and nine have assigned...

Wall Street Zen Downgrades CytomX Therapeutics (NASDAQ:CTMX) to Strong Sell

Wall Street Zen lowered shares of CytomX Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday...

CytomX Therapeutics (NASDAQ:CTMX) Stock Price Crosses Below 50-Day Moving Average - Here's What Happened

CytomX Therapeutics (NASDAQ:CTMX) Share Price Passes Below 50-Day Moving Average - What's Next...

$CTMX Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.09
• Reported revenue of $1.42M down -92.40% YoY

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

CytomX Therapeutics Inc

CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside

Equity

Bearish Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a winning week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$3.36
Prev Close	$3.35
Open	$3.34
Dividend Yield	0.00%
50-Day Moving Average	$3.36
Beta	1.45
Avg. Volume	3.44M
PE Ratio	-7.35

52-Week High	$8.21
52-Week Low	$1.89
Market Capitalization	$729.96M
EPS (Annual)	-$0.1477
Price to Book	2.42
Revenue Per Employee	$1.1M

Feed

News

Sentiment

Earnings

Fundamentals

Info